Novo Nordisk A/S remains a Strong Buy despite semaglutide's Alzheimer's trial miss. Click for NVO growth drivers, solid ...
The U.S. Food and Drug Administration has approved Novartis' gene therapy for patients with a rare muscle disorder, the drugmaker said on Monday.
Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal ...
The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions.
A new generation of weight-loss 'super-jabs' could help those who struggle to ditch the pounds with existing drugs, such as ...
A new generation of weight-loss 'super-jabs' could help those who struggle to ditch the pounds with existing drugs, such as ...
Shares of Biogen rose 3% following news of Novo's Alzheimer's trial failure. Biogen and partner Eisai's Leqembi and rival Eli ...
A pill version of A/S’s Ozempic failed to slow the progression of Alzheimer’s disease in a pair of long-shot studies that ...
The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...
Investor's Business Daily on MSN
Novo Dives After Weight-Loss Pill Fails In Alzheimer's Disease; Biogen Jumps
Novo Nordisk stock toppled Monday after its weight-loss pill failed to significantly slow the progression of Alzheimer's ...
A glimmer of hope for Alzheimer’s patients vanished Monday, when Novo Nordisk said a trial of an oral version of its weight loss drug Wegovy didn’t slow the progression of the disease in two large, ...
18h
Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says
An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback